Cover Image
市場調查報告書

乳癌治療藥的全球市場 (2016-2026年):單株抗體、荷爾蒙療法、化療、激化酵素抑制劑、其他藥劑的收益預測

Breast Cancer Drugs Market 2016-2026: Revenue Forecasts for Monoclonal Antibodies, Hormones, Chemotherapy, Kinase Inhibitors and Other Pharmaceuticals

出版商 Visiongain Ltd 商品編碼 125876
出版日期 內容資訊 英文 174 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
乳癌治療藥的全球市場 (2016-2026年):單株抗體、荷爾蒙療法、化療、激化酵素抑制劑、其他藥劑的收益預測 Breast Cancer Drugs Market 2016-2026: Revenue Forecasts for Monoclonal Antibodies, Hormones, Chemotherapy, Kinase Inhibitors and Other Pharmaceuticals
出版日期: 2016年03月16日 內容資訊: 英文 174 Pages
簡介

本報告提供全球乳癌治療藥的市場調查,乳癌概要、分類、治療方案,主要的治療藥概要、適應症、市場上地位、收益變化,研發產品線的現況與展望,市場成長的各種影響因素分析,藥物區分、各主要國家的收益規模的變化與預測,主要經營者、專家的採訪等彙整資料。

第1章 報告概要

第2章 乳癌與其治療:簡介

  • 所謂乳癌
  • 乳癌的分類
  • 治療方案

第3章 主要乳癌治療藥

  • Herceptin (trastuzumab):Roche
  • Perjeta (pertuzumab):Roche
  • Afinitor (everolimus):Novartis
  • Faslodex (fulvestrant):AstraZeneca
  • Ibrance (palbociclib):Pfizer
  • Avastin (bevacizumab):Roche
  • Kadcyla (ado-trastuzumab emtansine):Roche
  • Femara (letrozole):Novartis
  • Abraxane (paclitaxel Protein-Bound):Celgene

第4章 乳癌治療藥的研發產品線的預測

  • Roche
    • Taselisib (GDC-0032 / RG7604)
    • Atezolizumab (MPDL3280A / RG7446)
    • Kadcyla、Perjeta:適應症擴大的研究
  • Novartis
    • Buparlisib (BKM120)
    • Alpelisib (BYL719)
    • Ribociclib (LEE011)
  • AstraZeneca
    • AZD5363
    • MEDI-573 (MedImmune和合作)
  • Abemaciclib (LY2835219):Eli Lilly
    • FDA「Breakthrough Therapy Designation」指定
  • Veliparib (ABT-888):AbbVie
  • Ganetespib:Synta Pharmaceuticals
  • Entinostat:Syndax Pharmaceuticals
    • 和Merck及Roche合作、指定「Breakthrough Therapy Designation」
  • Lucitanib:Clovis Oncology
  • Glembatumumab vedotin (CDX-011):Celldex Therapeutics
    • EMERGE Study的成果
  • MM-302:Merrimack
    • 第一階段結果發表
  • Neratinib (PB272):Puma Biotechnology
  • ENMD-2076:CASI Pharmaceuticals
  • Margetuximab:MacroGenics

第5章 全球乳癌治療藥市場預測

  • 全球乳癌治療藥市場預測
  • 影響市場成長因素
  • 乳癌罹患率的擴大
  • 持有積極的研發產品線的動態且有前途的市場
  • 聯合治療的利用:患者、企業雙方而言的各種優點
  • 市場成長的障礙
  • 主要藥物的專利失效:跟學名藥、生技仿製藥的新競爭
  • 醫療費預算削減造成的成本壓力
  • 新治療藥的效力有限、嚴格的競爭
  • SWOT分析

第6章 全球乳癌治療藥市場預測:各主要藥物部門、各國

  • 市場預測:主要藥物部門
    • 藥物的市場結構:成果、預測
    • 單株抗體 (mAbs)
    • 化療、荷爾蒙療法
    • 激化酵素抑制劑
    • 其他
  • 市場預測:各主要國家
    • 主要國家市場預測
    • 地區結構:成果、預測
    • 美國
    • 歐盟5國
    • 日本
    • 金磚四國

第7章 調查採訪

  • Ken Ren博士 (Dr.), CEO of CASI Pharmaceuticals
  • MacroGenics

第8章 總論

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: PHA0099

Breast Cancer Therapies - Discover From 2016 What Revenues Are Possible

Are you interested in the breast cancer drug market's future? If so, you find that sales forecasting from 2016 in our new report. See there what is possible for those products and companies. You also explore trends, results and R&D, discovering opportunities and prospects.

Visiongain's study gives revenue predictions to 2026 at overall world market, submarket, product and national level. Avoid falling behind in data or losing influence. Instead discover what progress, opportunities and revenues those anti cancer drugs can achieve. See what is possible in that leading drugs market.

Please read on now to explore that industry and see what future revenue its expanding market could generate.

Original analysis to benefit your research, plans, decisions and proposals

The future holds great potential for pharma companies treating breast cancer. New products enter that market and novel drug candidates reach late-stage clinical testing. Discover, from 2016, revenues and other progress that are possible.

Besides revenue forecasting to 2026, our new work shows you recent results, sales growth rates and market shares. You assess research and development too. And in that report you gain 93 tables, 49 charts and interviews with two companies.

Our study's purpose is to help your research, analyses and decisions on breast cancer treatments, benefiting your authority and reputation for commercial insight. That way you can stay ahead in knowledge to help you stand out and succeed.

Although no single report covers everything, the following sections show how our new investigation benefits your work.

Forecasts covering the overall world market and segments for treating breast cancer

Discover in our new analysis revenue predictions to 2026 for breast cancer submarkets at world level. See what is possible for these four therapeutic classes:

  • Monoclonal antibodies (mAbs)
  • Chemotherapy and hormone therapy
  • Kinase inhibitors
  • Other medicines.

Where lie the best sales potentials? With our survey you assess outlooks for revenue expansion, seeing where you can gain. Also investigate competitors' actions and outlooks. Discover, from 2016, what is possible.

With a rising incidence of breast cancer worldwide and large patient populations, the demand for better treatments will continue to bolster that industry and market. Explore prospects for patients, healthcare providers and pharma companies.

Our new investigation also shows you revenue predications by product, exploring how those agents can succeed.

Forecasts for leading drugs - what sales are possible?

How will individual breast cancer medicines perform from 2016 to 2026 at world level? Our study forecasts revenues of these nine leading brands:

  • Herceptin (trastuzumab), Roche
  • Perjeta (pertuzumab), Roche
  • Afinitor (everolimus), Novartis
  • Faslodex (fulvestrant), AstraZeneca
  • Ibrance (palbociclib), Pfizer
  • Avastin (bevacizumab), Roche
  • Kadcyla (ado-trastuzumab emtansine), Roche
  • Femara (letrozole), Novartis
  • Abraxane (paclitaxel Protein-Bound), Celgene

Our investigation also forecasts sales of two biosimilar drug classes: trastuzumab and bevacizumab.

In that study you see how high revenues can go, finding products and years with highest predicted sales. You also examine competition. That way you investigate what is happening, understanding challenges, trends, competitors and opportunities.

Discover what the future holds for treating breast cancer. Our work also shows you geographical sales predictions.

National markets - what outlooks for those anticancer drug revenues?

Advances in the biopharma industry expand the range and use of medicines to treat breast cancer in developed and developing countries. Our work shows you individual revenue forecasts to 2026 for 11 leading national markets:

  • The United States
  • Japan
  • Germany, France, Italy, the United Kingdom and Spain (EU5 countries)
  • Brazil, Russia, India and China (BRIC group)

With our study you assess regions with highest revenues and potential sales growth. Explore outlooks for treating breast cancers, including discussions of patients' and healthcare providers' needs.

You also examine developments leading to novel and improved breast cancer medications.

R&D for those anticancer medicines - trends, innovations and progress

In our study you investigate research and development on breast cancer. You examine advances in oncology, assessing clinical trials and seeing what they show.

Our survey discusses 18 medicines in development for breast cancer, including these agents:

  • Taselisib (GDC-0032/RG7604), Roche
  • Atezolizumab (MPDL3280A/RG7446), Roche
  • Buparlisib (BKM120), Novartis
  • Alpelisib (BYL719), Novartis
  • Ribociclib (LEE011), Novartis
  • AZD5363, AstraZeneca
  • MEDI-573, AstraZeneca and MedImmune
  • Abemaciclib (LY2835219), Eli Lilly
  • Veliparib (ABT-888), AbbVie.

Our work shows you what is possible. R&D gains momentum from rising disease prevalence and other forces making treatments for that common cancer more widely used. See how demand increases.

Events and changes affecting companies treating breast cancer

Our study explains forces shaping the industry and market, letting you explore what is happening from 2016:

  • Extension of drugs' use - gaining approval for a wider indication range
  • Existing products and their futures - leading pharma companies' strategies
  • The race to gain drug approvals, especially from the FDA and EMA
  • Progress in clinical trials - finding the most promising medicines
  • Patent challenges - protecting intellectual property in a competitive market - the rise of generics and biosimilars
  • Combination therapies and other developments for biological drugs
  • Cost challenges - pricing and reimbursement, including proving value and clinical superiority.

You also gain SWOT analysis, assessing what drives and restrains that expanding anticancer drugs industry. See what shapes its market from 2016.

Our work shows what is possible for leading pharma companies and specialists in biological drugs and related biotechnologies for combating breast cancer.

Overall 2020 market value - what revenues are possible?

Our work predicts the world market for those drugs will reach $19.96bn in 2020. That industry will achieve revenue expansion from 2016 to 2026. With our analysis you discover how high sales can go, seeing what is possible for those drug companies.

For breast cancer therapies you assess leading drug developers, producers and marketers serving those therapeutic needs.

In our study you also discover interviews with CASI Pharmaceuticals and MacroGenics. See what the future holds for companies, exploring what they say and do, as well as their commercial prospects.

7 main ways Breast Cancer Drugs 2016-2026 helps your work

Our new investigation benefits your work in these seven main ways, helping you stay ahead in knowledge for your plans, decisions and proposals:

  • Revenues for breast cancer drugs to 2026 - assess that overall world market's potential, seeing scope for investments, production and marketing
  • Submarket revenues to 2026 covering 4 therapeutic segments - explore treatment categories, seeing their sales outlooks from 2016
  • Leading products' sales to 2026 - discover predicted revenues of 9 top drugs, assessing how well those medicines can compete and succeed
  • National market predictions to 2026 for 11 countries in the Americas, Europe and Asia - explore the best regions for demand, sales and growth
  • Research and development - see progress, trends and prospects in that oncological R&D, finding technological, clinical and commercial possibilities
  • Companies, news and opinions - examine participants in that rising market, gaining insight to help you stay ahead and benefit your influence
  • Analysis of what stimulates and restrains that market - assess challenges and strengths, helping you compete and gain advantages.

That analysis, by our in-house team in the UK, gives knowledge to benefit your research and plans. It shows data you find nowhere else. Gain information leading companies depend on.

Predictions for treating breast cancer - gain data to help you stay ahead

With our independent study you explore products, companies, progress and possibilities. Discover the best opportunities and assess commercial potentials.

Having that information means you are less likely to fall behind in knowledge or miss opportunity. Through your choice now, find how to save time and effort. Also benefit your plans, decisions, presentations, proposals and authority.

Our investigation shows you data, trends, opportunities and forecasts for that expanding anticancer market. Avoid missing out. Instead please get our new report here now.

visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1. Breast Cancer Drugs Overview
  • 1.2. Why you Should Read This Report
  • 1.3. How This Report Delivers
  • 1.4. Main Questions Answered by this Report
  • 1.5. Who is this Report for?
  • 1.6. Research and Analysis Methods
  • 1.7. Frequently Asked Questions (FAQ)
  • 1.8. Some Associated Reports
  • 1.9. About Visiongain

2. Introduction to Breast Cancer and its Treatment

  • 2.1. What is Breast Cancer?
  • 2.2. The Second Most Common Cancer in the World
  • 2.3. Normal Structure of the Human Breast
  • 2.4. Classifying the Different Types of Breast Cancer
    • 2.4.1. Pathology
    • 2.4.2. Molecular Subtype
    • 2.4.3. Stages
    • 2.4.4. Grades
  • 2.5. Treatment Protocols
    • 2.5.1. Treatment Options for Localised Disease
      • 2.5.1.1. The Different Types of Therapy for Localised Breast Cancer
      • 2.5.1.2. Stage 0-Lobular Carcinoma in Situ (LCIS) and Ductal Carcinoma in Situ (DCIS)
      • 2.5.1.3. Adjuvant Chemotherapy and Adjuvant Hormonal Therapy Treatment Options for Stage 1-3 Localised Disease
    • 2.5.2. Treatment Options for Recurrent or Metastatic Disease

3. Leading Breast Cancer Drugs

  • 3.1. Herceptin (trastuzumab) by Roche: The Leading Breast Cancer Drug
    • 3.1.1. Approved Indications: Breast Cancer is the Main Indication
    • 3.1.2. Roche Builds Franchise of Anti-HER2 mAbs Around Herceptin
    • 3.1.3. Total Herceptin Revenues 2010-2015
    • 3.1.4. The Threat of Biosimilars
      • 3.1.4.1. Hertraz and CanMab (Mylan and Biocon): The First to Win Approval
      • 3.1.4.2. Herzuma (Celltrion)
      • 3.1.4.3. Total Biosimilar Trastuzumab Revenue Forecast, for all Indications, 2016-2026
    • 3.1.5. Herceptin for Breast Cancer Revenue Forecast 2016-2026
  • 3.2. Perjeta (pertuzumab) by Roche
    • 3.2.1. Is a Recent Addition to the Market, Approved for Different Stages of Breast Cancer
    • 3.2.2. Positive Results from Different Clinical Trials
    • 3.2.3. Total Perjeta Revenues 2012-2015
    • 3.2.4. Perjeta for Breast Cancer Revenue Forecast 2016-2026
  • 3.3. Afinitor (everolimus) by Novartis
    • 3.3.1. Multiple Approved Indications but Breast Cancer Leads
    • 3.3.2. No Extension to HER2 Positive Breast Cancer, as Afinitor Fails to Meet Primary Objective in Phase 3 Trial
    • 3.3.3. NICE Rejects Afinitor on Cost Basis, although Drug Remains on the Cancer Drugs Fund, Despite Rumours it Would be Removed
    • 3.3.4. Total Afinitor Revenues 2010-2015
    • 3.3.5. Afinitor for Breast Cancer Revenue Forecast 2016-2026
  • 3.4. Faslodex (fulvestrant) by AstraZeneca
    • 3.4.1. Approved for Breast Cancer all the Way Back in 2002, Higher Dose Approved in 2010
    • 3.4.2. Patent Dispute with Mylan
    • 3.4.3. Total Faslodex Revenues 2010-2015
    • 3.4.4. Faslodex for Breast Cancer Revenue Forecast 2016-2026
  • 3.5. Ibrance (palbociclib) by Pfizer
    • 3.5.1. Accelerated Approval on the Back of Promising Data
    • 3.5.2. Has Already Been Used to Treat Over 15,000 Patients, MAA Filed in Europe
    • 3.5.3. Total Ibrance Revenues Q1-Q4 2015
    • 3.5.4. Ibrance for Breast Cancer Revenue Forecast 2016-2026
  • 3.6. Avastin (bevacizumab) by Roche
    • 3.6.1. Multiple Approved Indications, Still Approved for Breast Cancer in Major Markets, Except for the US
      • 3.6.1.1. Why was the FDA-Breast Cancer Label Withdrawn?
    • 3.6.2. Total Avastin Revenues 2010-2015
    • 3.6.3. Avastin for Breast Cancer Revenue Forecast 2016-2026
    • 3.6.4. No Biosimilars Approved yet, but Multiple Candidates in Clinical Trials
    • 3.6.5. Total Biosimilar Bevacizumab Revenue Forecast, for all Indications, 2016-2026
  • 3.7. Kadcyla (ado-trastuzumab emtansine) by Roche
    • 3.7.1. The First Antibody-Drug Conjugate to be Approved for Breast Cancer
    • 3.7.2. Mixed Results from Different Clinical Trials
    • 3.7.3. Total Kadcyla Revenues 2013-2015
    • 3.7.4. Kadcyla for Breast Cancer Revenue Forecast 2016-2026
  • 3.8. Femara (letrozole) by Novartis
    • 3.8.1. Hormone Therapy for Early Breast Cancer
    • 3.8.2. Total Femara Revenues 2010-2025
    • 3.8.3. Femara for Breast Cancer Revenue Forecast 2016-2026
  • 3.9. Abraxane (paclitaxel Protein-Bound) by Celgene
    • 3.9.1. Breast Cancer was the first of its Approved Indications
    • 3.9.2. Total Abraxane Revenues 2010-2015
    • 3.9.3. Abraxane for Breast Cancer Revenue Forecast 2016-2026

4. Breast Cancer Drugs R&D Pipeline 2016-2026

  • 4.1. Roche: Not Content with Dominating Current Market, Already Grooming Future Leaders
    • 4.1.1. Taselisib (GDC-0032 / RG7604)
      • 4.1.1.1. Positive Results from Phase 1 Trial
    • 4.1.2. Atezolizumab (MPDL3280A / RG7446)
      • 4.1.2.1. Early Results in Triple-Negative Breast Cancer
    • 4.1.3. Investigating Kadcyla and Perjeta in Wider Breast Cancer Indications
  • 4.2. Novartis
    • 4.2.1. Buparlisib (BKM120)
      • 4.2.1.1. Early-Results for Buparlisib in Combination with Olaparib
    • 4.2.2. Alpelisib (BYL719)
    • 4.2.3. Ribociclib (LEE011)
      • 4.2.3.1. Phase 1b Results in Combination with Femara
  • 4.3. AstraZeneca
    • 4.3.1. AZD5363
      • 4.3.1.1. Well Tolerated and Yielding Partial Response in Early Results from 2013
    • 4.3.2. MEDI-573 (In Partnership with MedImmune)
  • 4.4. Abemaciclib (LY2835219) by Eli Lilly
    • 4.4.1. Coveted Breakthrough Therapy Designation from the FDA
  • 4.5. Veliparib (ABT-888) by AbbVie
  • 4.6. Ganetespib by Synta Pharmaceuticals
  • 4.7. Entinostat by Syndax Pharmaceuticals
    • 4.7.1. Syndax Collaborating with Merck and Roche, Breakthrough Therapy Designation
  • 4.8. Lucitanib by Clovis Oncology
  • 4.9. Glembatumumab vedotin (CDX-011) by Celldex Therapeutics
    • 4.9.1. Results from EMERGE Study
  • 4.10. MM-302 by Merrimack
    • 4.10.1. Phase 1 Results Released April 2015
  • 4.11. Neratinib (PB272) by Puma Biotechnology
  • 4.12. ENMD-2076 by CASI Pharmaceuticals
  • 4.13. Margetuximab by MacroGenics

5. Global Breast Cancer Drugs Market 2016-2026

  • 5.1. The Global Breast Cancer Drugs Market Forecast 2016-2026
  • 5.2. What Factors will Drive Growth in the Global Breast Cancer Drugs Market?
  • 5.3. Increasing Rate of Breast Cancer
    • 5.3.1. What Factors are Contributing to this Increase?
  • 5.4. Dynamic and Lucrative Sector with Strong R&D Pipeline
  • 5.5. The Use of Combination Therapies Brings Various Benefits to Both Patients and Companies
  • 5.6. What Factors will Restrain Growth in the Breast Cancer Drugs Market?
  • 5.7. Patent Expiries for Key Drugs Will Open up Market to Generic and Biosimilar Competition
  • 5.8. Declining Healthcare Budgets Lead to Cost Pressures
  • 5.9. New Therapies that Only Offer Modest Benefits over Existing Treatments, and Intense Competition
  • 5.10. SWOT Analysis of the Global Breast Cancer Drugs Market

6. Leading Therapeutic Segments and National Markets within the Global Breast Cancer Drugs Market

  • 6.1. The Main Therapeutic Segments within the Breast Cancer Drugs Market, Forecast 2016-2026
    • 6.1.1. Therapeutic Composition of the Market in 2015, 2020 and 2026
    • 6.1.2. Monoclonal Antibodies (mAbs) Segment Forecast 2016-2026
    • 6.1.3. Chemotherapy and Hormone Therapy Segment
    • 6.1.4. Kinase Inhibitor Segment Forecast 2016-2026
    • 6.1.5. ‘Other' Segment Forecast 2016-2026
  • 6.2. Leading National Markets for Breast Cancer Drugs
    • 6.2.1. Leading Regional Markets for Breast Cancer, Forecast 2016-2026
    • 6.2.2. Regional Composition of the Market in 2015, 2020 and 2026
    • 6.2.3. US Breast Cancer Drugs Market 2016-2026
      • 6.2.3.1. The Dominant National Market, and will Remain so Throughout the Forecast Period, Although is Undergoing Some Changes
      • 6.2.3.2. US Breast Cancer Drugs Market Forecast 2016-2026
    • 6.2.4. EU5 Breast Cancer Drugs Market 2016-2026
      • 6.2.4.1. German Breast Cancer Drugs Market: The Leading EU Market, Undergoing Reforms
      • 6.2.4.2. German Breast Cancer Drugs Market Forecast 2016-2026
      • 6.2.4.3. French Breast Cancer Drugs Market: Some Reduction in Healthcare Spending, but National Healthcare System Remains Strong
      • 6.2.4.4. French Breast Cancer Drugs Market Forecast 2016-2026
      • 6.2.4.5. Italian Breast Cancer Drugs Market: Facing Challenges
      • 6.2.4.6. Italian Breast Cancer Drugs Market Forecast 2016-2026
      • 6.2.4.7. UK Breast Cancer Drugs Market: Pricing is a Contentious Issue
      • 6.2.4.8. UK Breast Cancer Drugs Market Forecast 2016-2026
      • 6.2.4.9. Spanish Breast Cancer Drugs Market
      • 6.2.4.10. Spanish Breast Cancer Drugs Market Forecast 2016-2026
    • 6.2.5. Japanese Breast Cancer Drugs Market
      • 6.2.5.1. Rapidly Ageing Population will Boost the Market, but will a Successful Generic Market be Established?
      • 6.2.5.2. Japanese Breast Cancer Drugs Market Forecast 2016-2026
    • 6.2.6. BRIC Breast Cancer Drugs Market
      • 6.2.6.1. Chinese Breast Cancer Drugs Market: Nation to Become one of the Major Global Players due to Rapid Growth
      • 6.2.6.2. Chinese Breast Cancer Drugs Market Forecast 2016-2026
      • 6.2.6.3. Brazilian Breast Cancer Drugs Market: Healthcare in the Country is Taking Great Strides Forward
      • 6.2.6.4. Brazilian Breast Cancer Drugs Market Forecast 2016-2026
      • 6.2.6.5. Russian Breast Cancer Drugs Market: Punches Below its Weight
      • 6.2.6.6. Russian Breast Cancer Drugs Market Forecast 2016-2026
      • 6.2.6.7. Indian Breast Cancer Drugs Market: Generics are King
      • 6.2.6.8. Indian Breast Cancer Drugs Market Forecast 2016-2026

7. Research Interviews

  • 7.1. Interview with Dr Ken Ren, CEO of CASI Pharmaceuticals
    • 7.1.1. On ENMD-2076 for Triple Negative Breast Cancer
    • 7.1.2. Status of the Chinese Oncology Market
    • 7.1.3. On the Properties that will Allow CASI to compete Against Giants in the Market, Such as Roche
    • 7.1.4. On Drivers and Restraints for the Market
    • 7.1.5. On the Challenges of Developing a Pipeline Product for the Breast Cancer Market, and Ways of Overcoming Them
  • 7.2. Interview with MacroGenics
    • 7.2.1. On Margetuximab for Metastatic Breast Cancer
    • 7.2.2. On Where Margetuximab would fit into the Competitive HER2 Space
    • 7.2.3. On the Challenges of Developing a Pipeline Product

8. Conclusions from Our Research and Analysis

  • 8.1. How will Revenues Change over the Forecast Period?
  • 8.2. How will the Therapeutic Composition of the Market Change over the Forecast Period?
  • 8.3. How will the Composition of the Global Market Change Over the Forecast Period?
  • 8.4. Concluding Remarks

List of Tables

  • Table 1.1: Regional Forecasts for the Global Breast Cancer Drugs Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2014-2020: SAMPLE
  • Table 2.1: Components of the Human Breast
  • Table 2.2: Classifying Breast Cancer by Pathology
  • Table 2.3: Different Molecular Subtypes of Breast Cancer
  • Table 2.4: Staging of Breast Cancer
  • Table 2.5: The Different Grades of Invasive Breast Cancer
  • Table 2.6: Key Terms in the Treatment of Early-Stage Breast Cancer
  • Table 2.7: Management Options for Stage 0 LCIS
  • Table 3.1: Herceptin Approved Indications and FDA-Approval History
  • Table 3.2: Total Herceptin Revenues 2010-2015: Revenues ($bn), AGR (%), CAGR (%)
  • Table 3.3: Biosimilar Trastuzumab Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2014-2020
  • Table 3.4: Biosimilar Trastuzumab Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2021-2026
  • Table 3.5: Herceptin for Breast Cancer Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2014-2020
  • Table 3.6: Herceptin for Breast Cancer Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2021-2026
  • Table 3.7: Perjeta Approved Indications and FDA-Approval History
  • Table 3.8: Total Perjeta Revenues 2012-2015: Revenues ($bn), AGR (%), CAGR (%)
  • Table 3.9: Perjeta for Breast Cancer Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2014-2020
  • Table 3.10: Perjeta for Breast Cancer Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2021-2026
  • Table 3.11: Herceptin: Approved Indications and FDA-Approval History
  • Table 3.12: Total Afinitor Revenues 2010-2015: Revenues ($bn), AGR (%), CAGR (%)
  • Table 3.13: Afinitor for Breast Cancer Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2014-2020
  • Table 3.14: Afinitor for Breast Cancer Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2021-2026
  • Table 3.15: Total Faslodex Revenues 2010-2015: Revenues ($bn), AGR (%), CAGR (%)
  • Table 3.16: Faslodex for Breast Cancer Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2014-2020
  • Table 3.17: Faslodex for Breast Cancer Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2021-2026
  • Table 3.18: Total Ibrance Revenues Q1 to Q4 2015: Revenues ($bn), Growth Rate (%), Average Growth Rate (%)
  • Table 3.19: Ibrance for Breast Cancer Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2015-2020
  • Table 3.20: Ibrance for Breast Cancer Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2021-2026
  • Table 3.21: Avastin Approved Indications and FDA-Approval History
  • Table 3.22: Total Avastin Revenues 2010-2015: Revenues ($bn), AGR (%), CAGR (%)
  • Table 3.23: Avastin for Breast Cancer Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2014-2020
  • Table 3.24: Avastin for Breast Cancer Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2021-2026
  • Table 3.25: Biosimilar Bevacizumab Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2014-2020
  • Table 3.26: Biosimilar Bevacizumab Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2021-2026
  • Table 3.27: Total Kadcyla Revenues 2013-2015: Revenues ($bn), AGR (%), CAGR (%)
  • Table 3.28: Kadcyla Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2014-2020
  • Table 3.29: Kadcyla Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2021-2026
  • Table 3.30: Total Femara Revenues 2010-2015: Revenues ($bn), AGR (%), CAGR (%)
  • Table 3.31: Femara Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2014-2020
  • Table 3.32: Femara Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2021-2026
  • Table 3.33: Abraxane Approved Indications and FDA-Approval History
  • Table 3.34: Total Abraxane Revenues 2010-2015: Revenues ($bn), AGR (%), CAGR (%)
  • Table 3.35: Abraxane Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2014-2020
  • Table 3.36: Abraxane Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2021-2026
  • Table 4.1: Taselisib (GDC-0032 / RG7604) Ongoing BC Clinical Trials, 2016
  • Table 4.2: Atezolizumab (MPDL3280A / RG7446) Ongoing BC Clinical Trials, 2016
  • Table 4.3: Clinical Investigation of Kadcyla and Perjeta in Wider BC Indications, 2016
  • Table 4.4: Buparlisib (BKM120) Selected Ongoing and Completed BC Clinical Trials, 2016
  • Table 4.5: Alpelisib (BYL719) Selected BC Clinical Trials, 2016
  • Table 4.6: Ribociclib (LEE011) Selected BC Clinical Trials, 2016
  • Table 4.7: AZD5363: Selected BC Ongoing Clinical Trials, 2016
  • Table 4.8: Abemaciclib (LY2835219): Selected Ongoing BC Clinical Trials, 2016
  • Table 4.9: Veliparib (ABT-888): Selected BC Clinical Trials, 2016
  • Table 4.10: Ganetespib Selected BC Clinical Trials, 2016
  • Table 4.11: MM-302 BC Clinical Trials, 2016
  • Table 4.12: Neratinib (PB272) Selected BC Clinical Trials, 2016
  • Table 4.13: Margetuximab Recent and Ongoing Clinical Trials, 2016
  • Table 5.1: Global Breast Cancer Drugs Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2014-2020
  • Table 5.2: Global Breast Cancer Drugs Market Forecast Revenue ($bn), AGR (%), CAGR (%), 2021-2026
  • Table 6.1: Therapeutic Segments within the Breast Cancer Drugs Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2014-2020
  • Table 6.2: Therapeutic Segments within the Breast Cancer Drugs Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2021-2026
  • Table 6.3: mAbs Segment of the Breast Cancer Market, Forecast: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2014-2020
  • Table 6.4: mAbs Segment of the Breast Cancer Market, Forecast: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2021-2026
  • Table 6.5: Chemotherapy and Hormone Therapy Segment of the Breast Cancer Market, Forecast: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2014-2020
  • Table 6.6: Chemotherapy and Hormone Therapy Segment of the Breast Cancer Market, Forecast: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2021-2026
  • Table 6.7: Kinase Inhibitor Segment of the Breast Cancer Market, Forecast: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2014-2020
  • Table 6.8: Kinase Inhibitor Segment of the Breast Cancer Market, Forecast: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2021-2026
  • Table 6.9: ‘Others' Segment of the Breast Cancer Market, Forecast: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2014-2020
  • Table 6.10: ‘Others' Segment of the Breast Cancer Market, Forecast: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2021-2026
  • Table 6.11: Regional Forecasts for the Global Breast Cancer Drugs Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2014-2020
  • Table 6.12: Regional Forecasts for the Global Breast Cancer Drugs Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2021-2026
  • Table 6.13: US Breast Cancer Drugs Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2014-2020
  • Table 6.14: US Breast Cancer Drugs Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2021-2026
  • Table 6.15: German Breast Cancer Drugs Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2014-2020
  • Table 6.16: German Breast Cancer Drugs Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2021-2026
  • Table 6.17: French Breast Cancer Drugs Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2014-2020
  • Table 6.18: French Breast Cancer Drugs Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2021-2026
  • Table 6.19: Italian Breast Cancer Drugs Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2014-2020
  • Table 6.20: Italian Breast Cancer Drugs Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2021-2026
  • Table 6.21: UK Breast Cancer Drugs Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2014-2020
  • Table 6.22: UK Breast Cancer Drugs Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2021-2026
  • Table 6.23: Spanish Breast Cancer Drugs Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2014-2020
  • Table 6.24: Spanish Breast Cancer Drugs Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2021-2026
  • Table 6.25: Japanese Breast Cancer Drugs Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2014-2020
  • Table 6.26: Japanese Breast Cancer Drugs Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2021-2026
  • Table 6.27: Chinese Breast Cancer Drugs Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2014-2020
  • Table 6.28: Chinese Breast Cancer Drugs Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2021-2026
  • Table 6.29: Brazilian Breast Cancer Drugs Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2014-2020
  • Table 6.30: Brazilian Breast Cancer Drugs Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2021-2026
  • Table 6.31: Russian Breast Cancer Drugs Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2014-2020
  • Table 6.32: Russian Breast Cancer Drugs Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2021-2026
  • Table 6.33: Indian Breast Cancer Drugs Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2014-2020
  • Table 6.34: Indian Breast Cancer Drugs Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2021-2026

List of Figures

  • Figure 3.1: Total Herceptin Revenues 2010-2015: Revenues ($bn)
  • Figure 3.2: Biosimilar Trastuzumab Revenue Forecast: Revenue ($bn), 2014-2026
  • Figure 3.3: Herceptin for Breast Cancer Revenue Forecast: Revenue ($bn), 2014-2026
  • Figure 3.4: Total Perjeta Revenues 2012-2015: Revenues ($bn)
  • Figure 3.5: Perjeta for Breast Cancer Revenue Forecast: Revenue ($bn), 2014-2026
  • Figure 3.6: Total Afinitor Revenues 2010-2015: Revenues ($bn)
  • Figure 3.7: Afinitor for Breast Cancer Revenue Forecast: Revenue ($bn), 2014-2026
  • Figure 3.8: Total Faslodex Revenues 2010-2015: Revenues ($bn)
  • Figure 3.9: Faslodex for Breast Cancer Revenue Forecast: Revenue ($bn), 2014-2026
  • Figure 3.10: Total Ibrance Revenues Q1-Q4 2015: Revenues ($bn)
  • Figure 3.11: Ibrance for Breast Cancer Revenue Forecast: Revenue ($bn), 2015-2026
  • Figure 3.12: Total Avastin Revenues 2010-2015: Revenues ($bn)
  • Figure 3.13: Avastin for Breast Cancer Revenue Forecast: Revenue ($bn), 2014-2026
  • Figure 3.14: Biosimilar Bevacizumab Revenue Forecast: Revenue ($bn), 2014-2026
  • Figure 3.15: Total Kadcyla Revenues 2013-2015: Revenues ($bn)
  • Figure 3.16: Kadcyla Revenue Forecast: Revenue ($bn), 2014-2026
  • Figure 3.17: Total Femara Revenues 2010-2015: Revenues ($bn)
  • Figure 3.18: Femara Revenue Forecast: Revenue ($bn), 2014-2026
  • Figure 3.19: Total Abraxane Revenues 2010-2015: Revenues ($bn)
  • Figure 3.20: Abraxane Revenue Forecast: Revenue ($bn), 2014-2026
  • Figure 5.1: Global Breast Cancer Drugs Market Forecast: Revenue ($bn), 2014-2026
  • Figure 5.2: SWOT Analysis of the Global Breast Cancer Drugs Market, 2016
  • Figure 6.1: Therapeutic Segments within the Breast Cancer Drugs Market: Revenues ($bn), 2014-2026
  • Figure 6.2: Therapeutic Composition of the Breast Cancer Drugs Market: Market Share (%), 2015
  • Figure 6.3: Therapeutic Composition of the Breast Cancer Drugs Market: Market Share (%), 2020
  • Figure 6.4: Therapeutic Composition of the Breast Cancer Drugs Market: Market Share (%), 2026
  • Figure 6.5: mAbs Segment of the Breast Cancer Market, Forecast: Revenues ($bn), 2014-2026
  • Figure 6.6: Chemotherapy and Hormone Therapy Segment of the Breast Cancer Market, Forecast: Revenues ($bn), 2014-2026
  • Figure 6.7: Kinase Inhibitor Segment of the Breast Cancer Market, Forecast: Revenues ($bn), 2014-2026
  • Figure 6.8: ‘Others' Segment of the Breast Cancer Market, Forecast: Revenues ($bn), 2014-2026
  • Figure 6.9: Regional Forecasts for the Global Breast Cancer Drugs Market: Revenues ($bn), 2014-2026
  • Figure 6.10: Regional Composition of the Global Breast Cancer Drugs Market: Revenues ($bn), Market Share (%), 2015
  • Figure 6.11: Regional Composition of the Global Breast Cancer Drugs Market: Revenues ($bn), Market Share (%), 2020
  • Figure 6.12: Regional Composition of the Global Breast Cancer Drugs Market: Revenues ($bn), Market Share (%), 2026
  • Figure 6.13: US Breast Cancer Drugs Market: Revenues ($bn), 2014-2026
  • Figure 6.14: German Breast Cancer Drugs Market: Revenues ($bn), 2014-2026
  • Figure 6.15: French Breast Cancer Drugs Market: Revenues ($bn), 2014-2026
  • Figure 6.16: Italian Breast Cancer Drugs Market: Revenues ($bn), 2014-2026
  • Figure 6.17: UK Breast Cancer Drugs Market: Revenues ($bn), 2014-2026
  • Figure 6.18: Spanish Breast Cancer Drugs Market: Revenues ($bn), 2014-2026
  • Figure 6.19: Japanese Breast Cancer Drugs Market: Revenues ($bn), 2014-2026
  • Figure 6.20: Chinese Breast Cancer Drugs Market: Revenues ($bn), 2014-2026
  • Figure 6.21: Brazilian Breast Cancer Drugs Market: Revenues ($bn), 2014-2026
  • Figure 6.22: Russian Breast Cancer Drugs Market: Revenues ($bn), 2014-2026
  • Figure 6.23: Indian Breast Cancer Drugs Market: Revenues ($bn), 2014-2026
  • Figure 8.1: Global Breast Cancer Drugs Market Forecast: Revenues ($bn), Annual Growth Rate (%), 2014-2026
  • Figure 8.2: Global Breast Cancer Drugs Market Broken Down by Therapeutic Segment: Revenues ($bn), 2014-2026
  • Figure 8.3: Leading National Markets for Breast Cancer Drugs: Revenues ($bn), 2015
  • Figure 8.4: Leading National Markets for Breast Cancer Drugs: Revenues ($bn), 2026

Companies Listed

  • AbbVie
  • Allergan
  • Amgen
  • Association of the British Pharmaceutical Industry
  • AstraZeneca
  • Biocad
  • Biocon
  • Boehringer Ingelheim
  • Cancer Research UK
  • CASI Pharmaceuticals
  • CDF (Cancer Drugs Fund)
  • Celgene
  • Celldex Therapeutics
  • Celltrion
  • CFDA
  • Chiba University Hospital
  • Clovis Oncology
  • EFPIA (European Federation of Pharmaceutical Industries and Associations)
  • Eli Lilly
  • EMA
  • Emcure Pharmaceuticals
  • FDA
  • Genentech
  • Globcan
  • IQWiG (German Institute for Quality and Efficiency in Health Care)
  • Italian National Health Service
  • MacroGenics
  • MedImmune
  • Merrimack
  • Ministry of Health, Labour and Welfare (Japan)
  • Mylan
  • NHS
  • NICE
  • Novartis
  • Novartis
  • Payment Advisory Board
  • Pfizer
  • Puma Biotechnology
  • Roche
  • Spectrum Pharmaceuticals
  • Swiss Re
  • Syndax Pharmaceuticals
  • Synta Pharmaceuticals
  • The American Association for Cancer
  • The Department of Health (UK)
  • Time magazine
  • UCLA
  • WHO (World Health Organization)
Back to Top